Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004808 | 0.92 | FAAH (0.49) | FAAHPLA2G2A | |
| SCHEMBL2169462 | 0.91 | FAAH (0.65) | FAAHPLA2G2AMEN1KMT2AMAPT | |
| SCHEMBL2168465 | 0.91 | PLA2G2A (0.66) | FAAHPLA2G2AMEN1KMT2AMAPT | |
| SCHEMBL2168730 | 0.90 | FAAH (0.62) | FAAHPLA2G2AMEN1KMT2AMAPT | |
| SCHEMBL2169306 | 0.90 | FAAH (0.62) | FAAHPLA2G2AMEN1KMT2AMAPT | |
| SCHEMBL3005007 | 0.88 | FAAH (0.46) | FAAHPLA2G2AMEN1KMT2AMAPT | |
| SCHEMBL2159931 | 0.88 | FAAH (0.68) | FAAHPLA2G2AMEN1KMT2AMAPT | |
| SCHEMBL3008722 | 0.87 | FAAH (0.51) | FAAHPLA2G2AMEN1KMT2AMAPT | |
| SCHEMBL2169467 | 0.86 | FAAH (0.70) | FAAHPLA2G2AMEN1KMT2AMAPT | |
| SCHEMBL2170314 | 0.85 | MEN1 (0.70) | FAAHPLA2G2AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | claimed |
| WO-2011123719-A2 | USE OF FAAH INHIBITORS FOR TREATING ABDOMINAL, VISCERAL AND PELVIC PAIN | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| WO-2011085216-A2 | USE OF FAAH INHIBITORS FOR TREATING PARKINSON'S DISEASE AND RESTLESS LEGS SYNDROME | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | claimed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | claimed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | QUEST VENTURES LTD. (GB) | 2013-06-13 | — | — | US | disclosed |
| WO-2011123719-A2 | USE OF FAAH INHIBITORS FOR TREATING ABDOMINAL, VISCERAL AND PELVIC PAIN | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011085216-A2 | USE OF FAAH INHIBITORS FOR TREATING PARKINSON'S DISEASE AND RESTLESS LEGS SYNDROME | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | FAAH, FAAH2, PNLIP | FAAH 1/4885PLA2G2A 26/4885MEN1 4757/4885 |
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | FAAH 109/4885PLA2G2A 3285/4885MEN1 3970/4885 |
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | FAAH 1/4885PLA2G2A 242/4885MEN1 4573/4885 |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | FAAH, FAAH2, MGLL | FAAH 1/4885PLA2G2A 108/4885MEN1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.